Hui WANG, M.D., Ph.D., Distinguished Professor, Ph.D. Supervisor

  Dean, School of Public Health

  Shanghai Jiao Tong University School of Medicine

  Phone: +86-21-53063539

  +86-21-63846590-776198

  Email: huiwang@shsmu.edu.cn

  http://sph.shsmu.edu.cn/

Prof. Wang was awarded National Science Fund for Distinguished Young Scholars, Top 10 China Young Women Scientist, National Talents Engineering of Ministry of Human Resources and Social Security of China in 2019, Outstanding Mid-Aged Expert, Scholar of the Hundred Talents Program from Chinese Academy of Sciences, Shanghai March Eighth red banner pacesetter, Shanghai Outstanding Academic Leader, Shanghai Leading Talent, Chief Scientist of the Grant “Science and Technology Coping with Active Health and Ageing” from the Ministry of Science and Technology of China.

Prof. Wang’s research has been working on active health and prevention and control of chronic diseases, basic and applied research of nutrition and food safety. She mainly focused on dissecting of the function and action mechanism of genetics, nutrition and food-borne risk factors and their interaction in personal chronic disease diagnosis, prevention and prognostic prediction. Furthermore, she’s also screening for new molecular target of cancer treatment and investigating the novel mechanism and strategies of nutritional and drug intervention in cancer prevention. She has published more than 120 original papers in prestigious journals (Nature Genetics, Gut, EHP, PNAS, Clin Cancer Res, etc) and has filed 30 patents (16 granted) with 7 translational products. Now there are 8 national and industrial standards established from these inventions. Based on these achievements, 1 Computer Software Copyright, 1 Software copyright of dietary survey, measurement and nutritional evaluation and 1 copyright of the video “Food Lab in Public Health” were also approved.

Currently Prof. Wang is the Expert Committee Member of the State Council Foodsafety Committee, Chief Member of the Microbiology Sub Committee of the 1st National Food Safety Standards Evaluation Cmmittee, the Expert Committee Member of the 2nd National Food Safety Risk Assessment, Vice Chief Member of Nutritional Translational Medicine Sub Committee of Chinese Nutrition Society, Council Member of the Chinese Society of Toxicology, Vice Chief Member of Food Toxicology Specialty Committee, Vice President of Shanghai Preventive Medicine Association, Director of the council of Society of Toxicology.

Research Interests：

1) Drug discovery and molecular pharmacology and toxicology

2) Nutrition & environment and disease prevention

3) Applied Nutriceutical Sciences and Food safety (including fast detection approach and the action mechanism of noxious substances in foods)

Publications：

1. Ge Y, Chen S, Mu W, Ba Q, Li J, Chen P, Wang X,Wang H*.Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma.Cancer Lett.Epub 2019 Mar 22. (*Corresponding author)

2. Li X#, Song L#, Hu X, Liu C, Shi J,Wang H*, Zhan L*, Song H*. Inhibition of Epithelial-Mesenchymal Transition and Tissue Regeneration by Waterborne Titanium Dioxide Nanoparticles.ACS Appl Mater Interfaces. 2018 Jan 31; 10(4):3449-3458.(*Corresponding author)

3.Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, Zhang H, Ying H, Ding Q, Song H, Liu H, Zhang RWang H*.Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein.Cell Discovery2017 Nov21;3:17042. (*Corresponding author)

4. Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X,Wang H*. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.GUT2017; 66(1):157-167. (*Corresponding author)

5. Ba Q, Li M, Chen P, Huang C, Duan X, Lu L, Li J, Chu R, Xie D, Song H, Wu Y, Ying H, Jia X,Wang H*.Sex-dependent effects of cadmium exposure in early life on gut microbiota and fat accumulation in mice.Environ Health Perspect2017, 125(3):437-44. (*Corresponding author)

6. Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y, Wang F, Duan X, Li J, Zhang W,Wang H*. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.EBioMedicine.2017 Aug;22:58-67. Epub 2017 Jul 18. (*Corresponding author)

7. Huang C, Sun M, Yang Y, Wang F, Ma X, Li J, Wang Y, Ding Q, Ying H, Song H, Wu Y, Jiang Y, Jia X, Ba Q,Wang H*. Titanium dioxide nanoparticles prime a specific activation state of macrophages.Nanotoxicology2017, 11(6):737-50. (*Corresponding author)

8. Ba Q, Li X, Huang C, Li J, Fu Y, Chen P, Duan J, Hao M, Zhang Y, Li J, Sun C, Ying H, Song H, Zhang R, Shen Z,Wang H*.BCCIPβ modulates the ribosomal and extraribosomal function of S7 through a direct interaction.J Mol Cell Biol.2017 May 16. [Epub ahead of print] (*Corresponding author)

9. Li C, Chen P, Duan X, Wang J, Shu B, Li X, Ba Q, Li J, Wang Y,Wang H*.Bioavailable 25(OH)D but not total 25(OH)D is an independent determinant for bone mineral density in Chinese postmenopausal women.Ebiomedicine.2017 Feb;15:184-192. (*Corresponding author)

10. Li X, Zhou Y, Liu Y, Zhang X, Chen T, Chen K, Ba Q, Li J, Liu H,Wang H*.Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer.Ebiomedicine2016 Dec;14:44-54. (*Corresponding author)

11. Chen P, Duan X, Li M, Huang C, Li J, Chu R, Ying H, Song H, Jia X, Ba Q,Wang H*.Systematic network assessment of the carcinogenic activities of cadmium.Toxicol Appl Pharmacol.2016 Nov 1;310:150-158. (*Corresponding author)

12. Chen P, Li M, Duan X, Jia J, Li J, Chu R, Yu C, Han J,Wang H*.Pharmacokinetics and effects of demographic factors on blood 25(OH)D3 levels after a single orally administered high dose of vitamin D3.Acta Pharmacol Sin.2016 Nov;37(11):1509-1515. (*Corresponding author)

13. Chen P, Li B, Zhu Y, Chen W, Liu X, Li M, Duan X, Yi B, Wang J, Liu C, Luo X, Li X, Li J, Liang J, Yin X,Wang H*, Jiang X. Establishment and Validation of a Prognostic Nomogram for Patients with Resectable Perihilar Cholangiocarcinoma.Oncotarget.2016 Jun 14;7(24):37319-37330. (*Corresponding author)

14. Ba Q, Huang C, Fu Y, Li J, Li J, Chu R, Jia X,Wang H*. Cumulative metabolic effects of low-dose benzo(a)pyrene exposure on human cells.Toxicology Research. 2016;5:107-115. (*Corresponding author)

15. Zhang X, Ba Q, Gu Z, Guo D, Zhou Y, Xu Y,Wang H*, Ye D, Liu H. Fluorescent Coumarin–Artemisinin Conjugates as Mitochondria-Targeting Theranostic Probes for Enhanced Anticancer Activities.Chemistry. 2015 Nov 23;21(48):17415-21. (*Corresponding author)

16. Ba Q, Li J, Huang C, Qiu H, Li J, Chu R, Zhang W, Xie D, Wu Y,Wang H*. Effects of benzo[a]pyrene exposure on human hepatocellular carcinoma cell angiogenesis, metastasis, and NF-κB signaling.Environ Health Perspect. 2015 Mar;123(3):246-54. (*Corresponding author)

17. Ba Q, Li J, Huang C, Li J, Chu R, Wu Y,Wang H*. Topological, functional, and dynamic properties of the protein interaction networks rewired by benzo(a)pyrene.Toxicol Appl Pharmacol. 2015 Mar 1;283(2):83-91. (*Corresponding author)

18.Wang W, Nag S, Zhang X, Wang MH,Wang H, Zhou J, Zhang R. Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications.Med Res Rev. 2015 Mar;35(2):225-85.

19. Salazar JK, Wang Y, Yu S,Wang H, Zhang W.Polymerase chain reaction-based serotyping of pathogenic bacteria in food.J Microbiol Methods. 2015 Jan 14;110C:18-26.

20.OuY, Chen P, Zhou Z, Li C, Liu J, Tajima K, Guo J, Cao J,Wang H*.Associations between variants on ADIPOQ and ADIPOR1 with colorectal cancer risk: a chinese case-control study and updated meta-analysis.BMC Med Genet. 2014 Dec 17;15(1):137.(*Corresponding author)

21. Wu X, Chen P, Ou Y, Liu J, Li C,Wang H*, Qiang F. Association of variants on ADIPOQ and AdipoR1 and the prognosis of gastric cancer patients after gastrectomy treatment.Mol Biol Rep. 2014 Oct 1.(*Corresponding author)

22. Wang W, Qin JJ, Voruganti S, Srivenugopal KS, Nag S, Patil S, Sharma H, Wang MH,Wang H, Buolamwini JK, Zhang R.The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.Nat Commun. 2014 Oct 1;5:5086.

23. Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J,Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R.Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice.Gastroenterology. 2014 Oct;147(4):893-902.e2.

24. Qin JJ, Nag S, Wang W, Zhou J, Zhang WD,Wang H, Zhang R.NFAT as cancer target: Mission possible?Biochim Biophys Acta. 2014 Jul 26;1846(2):297-311.

25. Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, Liu C, Shen B, Wang XA, Wu W, Zhou D, Zhang D, Wang T, Liu B, Qu K, Ding Q, Weng H, Ding Q, Mu J, Shu Y, Bao R, Cao Y, Chen P, Liu T, Jiang L, Hu Y, Dong P, Gu J, Lu W, Shi W, Lu J, Gong W, Tang Z, Zhang Y, Wang X, Chin YE, Weng X, Zhang H, Tang W, Zheng Y, He L,Wang H*, Liu Y, Liu Y. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.Nat Genet. 2014 Aug;46(8):872-6.(*Corresponding author)

26. Li M, Chen P, Li J, Chu R, Xie D,Wang H*.The Impacts of Circulating 25-Hydroxyvitamin D Levels on Cancer Patient Outcomes: a Systematic Review and Meta-Analysis.J Clin Endocrinol Metab. 2014 Jul;99(7):2327-36.(*Corresponding author)

27. Chen P, Li C, Li X, Li J, Chu R,Wang H*.Higher dietary folate intake reduces the breast cancer risk: a systematic review and meta-analysis.Br J Cancer.2014 Apr 29;110(9):2327-38.(*Corresponding author)

28. Li C, Chen P, Hu P, Li M, Li X, Guo H, Li J, Chu R, Zhang W,Wang H*. Folate intake and MTHFR polymorphism C677T is not associated with ovarian cancer risk: evidence from the meta-analysis.Mol Biol Rep.2013 Dec;40(12):6547-60.(*Corresponding author)

29. Huang C, Ba Q, Yue Q, Li J, Li J, Chu R,Wang H*. Artemisinin rewires the protein interaction network in cancer cells: network analysis, pathway identification, and target prediction.Mol Biosyst. 2013 Dec 29;9(12):3091-100.(*Corresponding author)

30. Li J, Ba Q, Yin J, Wu S, Zhuan F, Xu S, Li J, Salazar JK, Zhang W,Wang H*. Surface Display of Recombinant Drosophila melanogaster Acetylcholinesterase for Detection of Organic Phosphorus and Carbamate Pesticides.PLoS ONE.2013 Sep 9;8(9):e72986.(*Corresponding author)

31.LiuY, Li C, Chen P, Li X, Li M, Guo H, Li J, Chu R,Wang H*. Polymorphisms in the vitamin D receptor (VDR) and the risk of ovarian cancer: a meta-analysis.PLoS ONE. 2013 Jun 24;8(6):e66716.(*Corresponding author)

32. Li M, Chen PZ, Yue QX, Li JQ, Chu RA, Zhang W,Wang H*.Pungent ginger components modulates human cytochrome P450 enzymes in vitro.Acta Pharmacol Sin.2013 Sep 5;34(9):1237-42.(*Corresponding author)

33. Salazar JK, Wu Z, Yang W, Freitag NE, Tortorello ML,Wang H, Zhang W.Roles of a novel Crp/Fnr family transcription factor Lmo0753 in soil survival, biofilm production and surface attachment to fresh produce of Listeria monocytogenes.PLoS One. 2013 Sep 16;8(9):e75736.

34.SalazarJK, Deng K, Tortorello ML, Brandl MT,Wang H, Zhang W.Genes ycfR, sirA and yigG contribute to the surface attachment of Salmonella enterica Typhimurium and Saintpaul to fresh produce.PLoS One. 2013;8(2):e57272.

35. Hou W, Qin X, Zhu X, Fei M, Liu P, Liu L, Moon H, Zhang P, Greshock J, Bachman KE, Ye BC,Wang H*, Zang CY. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.Oncol Rep.2013 Aug;30(2):707-14.(*Corresponding author)

36.BaQ, Duan J, Tian JQ, Wang ZL, Chen T, Li XG, Chen PZ, Wu SJ, Xiang L, Li JQ, Chu RA,Wang H*Dihydroartemisinin promotes angiogenesis during the early embryonic development of zebrafish.Acta Pharmacol Sin.2013 Aug;34(8):1101-7.(*Corresponding author)

37. Li X, Yang X, Liu Y, Gong N, Yao W, Chen P, Qin J, Jin H, Li J, Chu R, Shan L, Zhang R, Zhang W,Wang H*. Japonicone A suppresses growth of Burkitt’s lymphoma cells through its effect on NF-κB.Clin Cancer Res.2013Jun 1;19(11):2917-28. (*Corresponding author)

38.LiX ,Chen T, Lin S, Zhao J, Chen P, Ba Q, Guo H, Liu Y, Li J, Chu R, Shan L , Zhang W andWang H*. Valeriana jatamansi Constituent IVHD-valtrate As a Novel Therapeutic Agent to Human Ovarian Cancer: in vitro and in vivo Activities and Mechanisms.Curr Cancer Drug Targets. 2013 May 1;13(4):472-83.(*Corresponding author)

39.ZhangX, Wang W,Wang H, Wang MH, Xu W, Zhang R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop.Oncogene.2013 May 30;32(22):2782-91.

40.ZhaoX, Yue Q, Xie Z, Li T, Huang G, Li J,Wang H*. The application of proteomics in the research of traditional Chinese medicine complex system.Chinese Bulletin of Life Sciences. 2013 Mar;25(3):334-41.(*Corresponding author)

41.LiM, Chen P, Li X,Wang H*. Vitamin D and cancer: present status and future prospects.Chinese Bulletin of Life Sciences. 2013 Feb;25(2):218-30.(*Corresponding author)

42.ChenP, Li M, Gu X, Liu Y, Li X, Li C, Wang Y, Xie D, Wang F, Yu C, Li J, Chen X, Chu R, Zhu J, Ou Z,Wang H*.Higher Blood 25(OH)D Level May Reduce the Breast Cancer Risk: Evidence from a Chinese Population Based Case-Control Study and Meta-Analysis of the Observational Studies.PLoS ONE.2013;8(1):e49312.(*Corresponding author)

43.LinS, Zhang ZX, Chen T, Ye J, Dai WX, Shan L, Su J, Shen YH, Li HL, Liu RH, Xu XK,Wang H*, Zhang WD.Characterization of chlorinated valepotriates from Valeriana jatamansi.Phytochemistry. 2013 Jan;85:185-93.(*Corresponding author)

44.BaQ, Zhou N, Duan J, Chen T, Hao M, Yang X, Li J, Yin J, Chu R,Wang H*.Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1.PLoS ONE.2012;7(8):e42703.(*Corresponding author)

45.ZhangX, Zhang Z, Cheng J, Li M, Wang W, Xu W,Wang H, Zhang R. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.J Biol Chem.2012 Aug 31;287(36):30468-76.

46.BaQ, Hao M, Huang H, Hou J, Ge S, Zhang Z, Yin J, Chu R, Jiang H, Wang F, Chen K, Liu H andWang H*. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies.Clin Cancer Res. 2011 Dec 15;17(24):7625-33.(*Corresponding author)

47.ChenT, Xu Y, Guo H, Liu Y, Hu P, Yang X, Li X, Ge S, Velu S, Nadkarni D, Wang W, Zhang R andWang H*. Experimental therapy of ovarian cancer with synthetic Makaluvamine Analog: In vitro and in vivo anticancer activity and molecular mechanisms of action.PLoS ONE.2011;6(6):e20729.(*Corresponding author)

48.DuanJ, Ba Q, Wang Z, Hao M, Hu P, Li X, Zhang D, Zhang R andWang H*. Knockdown of Ribosomal Protein S7 Causes Developmental Abnormalities via p53 Dependent and Independent Pathways in Zebrafish.Int J Biochem Cell Biol.2011 Aug;43(8):1218-27.(*Corresponding author)

49.GuoD, Chen T, Ye D, Xu j, Jiang H, Chen K,Wang H*and Liu H. Cell-permeable Iminocoumarine-based Fluorescent Dyes for Mitochondria.Organic Letters. 2011 Jun 3;13(11):2884-7.(*Corresponding author)

50.Li M, Zhou Y, Chen P, Yang H, Yuan X, Tajima K, Cao J andWang H *. Genetic Variants on Chromosome 8q24 and Colorectal Neoplasia Risk: A Case-control Study in China and a Meta-analysis of the Published Literature.PLoS ONE.2011 Mar; 6(3):e18251.(*Corresponding author)

51.HaoM, Wang W, Zhao Y, Zhang R andWang H*. Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors.Eur J Drug Metab Pharmacokinet.2011 Jan;35(3-4):109-13.(*Corresponding author)

52.FengY, Wang T, Deng Y, Yang P, Li J, Guan D, Yao F, Zhu Y, Qin Y,Wang H, Li N, Wu M, Wang H,Wang X, Cheng S and Xie D. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.Hepatology.2011 Feb;53(2):483-92.

53.HaoM, Ba Q, Yin J, Li J, Zhao Y andWang H*. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides.Drug Metabolism and Pharmacokinetics.2011;26(2):201-5.(*Corresponding author)

54. Tang H, Pang S, Wang M, Xiao X, Rong Y,Wang H, Zang YQ. TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice.J Immunol.2010 Aug 15;185(4):2563-9.

55. Liang J, Chen P, Hu Z, Shen H, Wang F, Chen L, Li M, Tang J,Wang H*and Shen H. Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population.Breast Cancer Res Treat.2010 Nov;124(1):237-41. (*Corresponding author)

56. Feng Y, Ding X, Chen T, Chen L, Liu F, Jia X, Luo X, Shen X, Chen K, Jiang H,Wang H*, Liu H, Liu D. Design, synthesis and interaction study of quinazoline-2(1H)-thione derivatives as potential novel Bcl-xL Inhibitors.J Med Chem.2010 May 13;53(9):3465-79. (*Corresponding author)

57. Lin S, Chen T, Liu XH, Shen YH, Li HL, Shan L, Liu RH, Xu XK, Zhang WD,Wang H*. Iridoids and Lignans from Valeriana jatamansi.J Nat Prod.2010 Apr 23;73(4):632-8. (*Corresponding author)

58. Chen P, Hu P, Xie D, Qin Y, Wang F, andWang H*. Meta-analysis of Vitamin D, Calcium and the Prevention of Breast Cancer.Breast Cancer Res Treat.2010 Jun;121(2):469-77. (*Corresponding author)

59. Chen T, Li M, Zhang R, andWang H*. Dihydroartemisinin Induces Apoptosis and Sensitizes Human Ovarian Cancer Cells to Carboplatin Therapy.J Cell Mol Med.2009 Jul;13(7):1358-70. (*Corresponding author)

60. Lin S, Shen YH, Li HL, Yang XW, Chen T, Lu LH, Huang ZS, Liu RH, Xu XK, Zhang WD,Wang H*.Acylated iridoids with cytotoxicity from Valeriana jatamansi.J Nat Prod.2009 Apr;72(4):650-5. (*Corresponding author)

61. Chen D, Zhang J, Li M, Rayburn ER,Wang H, Zhang R.RYBP stabilizes p53 by modulating MDM2.EMBO Rep. 2009 Feb;10(2):166-72.

62. Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, Wang Y, Tang J,Wang H*and Shen H. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women.Carcinogenesis.2008 Dec;29(12):2341-6. (*Corresponding author)

63. Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, andWang H*. Association of Common PALB2 Polymorphisms with Breast Cancer Risk: a Case-Control Study.Clin Cancer Res. 2008. Sep 15; 14 (8): 5931-37. (*Corresponding author)

64. Hou J, Wang D, Zhang R, andWang H*. Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action.Clin Cancer Res.2008 Sep 1; 14(17):5519-30. (*Corresponding author)

65. Hao M, Zhao Y, Chen P, Huang H, Liu H, Zhang R, andWang H*. Structure-Activity Relationship and Substrate-dependent Phenomena in Effects of Ginsenosides on Activities of Drug-metabolizing P450 Isozymes.PLoS ONE. 2008 Jul 16;3(7):e2697. (*Corresponding author)

66. Wang W,Wang H*, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer: activity in vitro and in vivo and mechanisms of action.Br J Cancer.2008 Feb 26;98(4):792-802. (*Corresponding author)

67. Wang W, Rayburn ER, Hao M, Zhao Y, Hill DL, Zhang R,Wang H*. Experimental Therapy of Prostate Cancer with Novel Natural Product Anti-cancer Ginsenosides.Prostate.2008 Mar 6;68(8):809-819. (*Corresponding author)

68. Chen T, ChenL,Wang H*. Role of Survivin in Ovarain Cancer.J Intl Obste and Gynecol.2008, 35 (3): 184-187. (*Corresponding author)

69. Saif MW, Sellers S, Li M, Wang W, Cusimano L,Wang H, Zhang R. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.Cancer Chemother Pharmacol.2007 Nov;60(6):871-82.

70. Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL,Wang H*, Zhang R. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function.Oncogene. 2007 Aug 2;26(35):5029-37. (*Corresponding author)

71. Rayburn E, Wang W, Zhang R.,Wang H*. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.Intl J Oncol.2007 Jun;30(6):1511-9. (*Corresponding author)

72. He J, Zhou F, Shao K, Hang J,Wang H, Rayburn E, Xiao Z, Lee SW. Xue Q, Feng X, Shi S, Zhang C, Zhang S. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases.Lung Cancer.2007 Apr;56(1):51-58.

73. Wang W, Zhao Y, Rayburn E, Hill DL,Wang H, Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng.Cancer Chem Pharm.2007 Apr;59(5):589-601.

74.Wang H*, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics.Intl J Oncol.2007 Apr;30(4):947-53. (*Corresponding author)

75.Wang H, Li M, Lin W, Wang W, Zhang Z, Rayburn E, Lu J, Chen D, Yue X, Shen F, Jiang F, He J, Wei W, Zeng X. Zhang R. Extracellular activity of cAMP-dependent protein kinase (ECPKA) as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients.Can Epidem Biomarker Prev.2007 Apr;16(4):789-95.

76. Li M, Zhang Z, Hill DL,Wang H, Zhang R. Curcumin, a dietary component, has anti-cancer, chemosensitization and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3 kinase/mTOR/ETS2 pathway.Cancer Res.2007 Mar 1;67(5):1988-96.

77. Zhao Y, Wang W, Rayburn E, Hill DL,Wang H, Zhang R. Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng.Med Chem. 2007;3:51-60.

78. Rayburn E, Wang W, Zhang Z, Li M, Zhang R,Wang H*. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.Prostate.2006 Nov 1;66(15):1653-63. (*Corresponding author)

79. Wang Z,Wang H, Rhie JK, Covey JM, Liang P, Wang S, Wang C, Hu Y, Prasad G, Nan L, Hill DL, Zhang R. Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.J Pharm Biomed Anal. 2006 Sep 18; 42(2):272-6.

80. LaCasse EC, Cherton-Horvat GG, Hewitt KE, Morris SJ, Kandimalla ER, Yu D,Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP. Preclinical characterization of AEG35156/GEM640, a second generation antisense oligonucleotide targeting XIAP.Clin Cancer Res.2006 Sep 1;12(17):5231-41.

81.Wang H, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anti-cancer activity and potentiation of antibody therapy.Mol Cancer Ther.2006 Aug;5(8):2106-14.

82. Zhang R andWang H. Antisense strategies for the development of novel cancer therapeutics. In: A.A. Adjei and J.K. Buolamwini, eds. Novel Anticancer Agents Strategies for Discovery and Clinical Testing. Elsevier Science, New York, NY. 2006; pp 193-206.

83. Li M,Wang H*, Hill DL, Stinson S, Veley K, Grossi I, Peggins J, Covey JM, Zhang R. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.Cancer Chemother Pharm.2006;57(5):607-614. (*Corresponding author)

84. Rayburn ER,Wang H, Zhang R. Antisense-based cancer therapeutics: are we there yet?Expert Opinion on Emerging Drugs.2006;11(2):337-52.

85.Wang H, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting TLR9.Mol Cancer Ther.2006;5(6):1585-92.

86. Zhang Z,Wang H, Li M, Agrawal S, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.Oncogene. 2005 Nov 3;24(48):7238-47.

87. Zhang Z,Wang H, Li M, Rayburn E, Agrawal S, Zhang R. Novel MDM2 p53-independent functions identified through RNA silencing technologies.Ann N Y Acad Sci.2005 Nov;1058:205-14.

88. Li M, Zhang Z, Hill D, Chen X,Wang H, Zhang R. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels.Cancer Res.2005 Sep 15;65(18):8200-8.

89. Zhang Z, Li M, Rayburn E, Hill DL, Zhang R,Wang H*. Oncogenes as novel targets for cancer Therapy (part I): Growth factors and protein tyrosine kinases.Am J Pharmacogenomics.2005;5(3):173-90. (*Corresponding author)

90. Zhang Z, Li M, Rayburn E, Hill DL, Zhang R,Wang H*. Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.Am J Pharmacogenomics.2005;5(4):247-57. (*Corresponding author)

91. Zhang Z, Li M, Rayburn E, Hill DL, Zhang R,Wang H*. Oncogenes as novel targets for cancer therapy ((Part III): Transcription.Am J Pharmacogenomics. 2005;5(5):327-38. (*Corresponding author)

92. Zhang Z, Li M, Rayburn E, Hill DL, Zhang R,Wang H*. Oncogenes as novel targets for cancer therapy (Part IV): Regulators of the cell cycle, DNA damage repair and apoptosis.Am J Pharmacogenomics.2005;5(6):397-407. (*Corresponding author)

93.Wang H, Rayburn E, Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anti-cancer therapeutics.Curr Pharm Des.2005 Aug;11(22):2889-907.

94.Wang H*, Li M, Rhie JK, Hockenbery DM, Covey JM, Zhang R, Hill DL. Preclinical pharmacology of 2-Methoxyantimycin A compounds as novel antitumor agents.Cancer Chemother Pharm.2005 May 10;56(3):291-8. (*Corresponding author)

95.Wang H*, Wang Z, Wang S, Li M, Nan L, Rhie JK, Covey JM, Zhang R, Hill DL. Preclinical pharmacology of Epothilone D, a novel tubulin-stabilizing antitumor agent.Cancer Chemother Pharm.2005 May 3;56(3):255-60. (*Corresponding author)

96. Posey JA,Wang H, Hamilton J, Delgrosso A, Zhang R, Freda T, Zamboni WC. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.Cancer Chemother Pharmacol.2005 Apr;56(2):182-8.

97. Zhang R,Wang H, Agrawal S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: Proof of principle, in vitro and in vivo activities, and Mechanisms.Curr Cancer Drug Targets.2005 Feb;5(4):43-50.

98. Rayburn E, Zhang R, He J,Wang H*. MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy.Curr Cancer Drug Targets.2005 Feb;5(1):27-42. (*Corresponding author)

99. Rayburn E,Wang H, He J, Zhang R. RNA silencing technologies in drug discovery and target validation. Letters in Drug Design and Discovery. 2005 Feb;2(1):1-18.

100.Rayburn E, Wang W, Zhang R, andWang H*. Antisense approach in drug discovery and development.Prog Drug Res.2005;63:227-74. (*Corresponding author)

101.Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, Park JK,Wang H, Peng Y, Jiang W, He TC. Wnt/beta-catenin signaling pathway as a novel cancer drug target.Curr Cancer Drug Targets.2004 Dec;4(8):653-71.

102.Prasad G,Wang H, Hill DL, Zhang R. Recent advances in experimental molecular therapeutics for malignant gliomas.Curr Med Chem-Anti-Ca Agents.2004 Jul;4(4):347-61.

103.Wang H, Li M, Rinehart JJ, Zhang R. Dexamethasone as a chemoprotectant in cancer chemotherapy: Hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine.Cancer Chemother Pharm.2004 Jun;53(6):459-67.

104.Zhang Z,Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21(WAF1/CIP1), independent of p53.J Biol Chem.2004 Apr;279(6):16000-6.

105.Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: in vivo activity, pharmacokinetics and clinical implications for cancer chemotherapy.Clin Cancer Res. 2004 Mar;10(5):1633-44. (Featured article)

106.Zhang Z*,Wang H*, Prasad G*, Li M, Yu D, Bonner J, Agrawal S, Zhang R. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.Clin Cancer Res.2004 Feb 15;10(4):1263-73. (*Co-first author) (Featured article)

107.Zhang R,Wang H. Antisense technology. In: D. T. Curiel and J.T. Douglas: Contemporary Cancer Research: Cancer Gene Therapy. Humana Press, Totowa, NJ, 2004; pp 35-49.

108.Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. Chemosensitization and radiosensitization of human cancer by antisense Anti-MDM2 Oligonucleotides: in vitro and in vivo activities and mechanisms.Ann N Y Acad Sci.2003 Dec;1002:217-35.

109.Zhang Z, Li M,Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.Proc Natl Acad Sci U S A.2003 Sep 30;100(20):11636-41.

110.Zhang R andWang H. Antisense oligonucleotides targeting RIa subunit of protein kinase A; in vitro and in vivo antitumor activity and pharmacokinetics.Methods Mol Med.2003;75:637-54.

111.Zhang R andWang H. Antisense oligonucleotide inhibitors of MDM2 oncogene expression. Methods Mol Med. 2003; 85: 205-22.

112.Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J,Wang H, Huang P, Zhang R, Agrawal S. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles.Nucleic Acids Res.2003 May 1;31(9):2393-400.

113.Wang H, Yu D, Agrawal S, Zhang R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.Prostate.2003 Feb 15;54(3):194-205.

114.Bhagat L, Zhu FG, Yu D, Tang J, Wang H, Kandimalla ER, Zhang R, Agrawal S. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents.Biochem Biophys Res Comm.2003 Jan 24;300(4):853-61.

115.Zhang R andWang H. Modulation of gene expression by antisense oligonucleotides. In: S. W. Kim and R.I. Mahato eds: Pharmaceutical Perspectives of Nucleic acid-based Therapeutics. Taylor & Francis: London, UK. 2002;pp33-53.

116.Yu D, Zhu F, Bhagat L,Wang H, Kandimalla ER, Zhang R, Agrawal S. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties.Biochem Biophys Res Comm.2002 Sep;297(1):83-90.

117.Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.Int J Oncol.2002 Jul;21(1):73-80.

118.Wang H, Oliver P, Nan L, Wang S, Wang Z, Rhie JK, Zhang R, Hill DL. Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice.Cancer Chemother Pharmacol. 2002 May;49(5):419-24.

119.Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.Int J Oncol.2002 Apr;20(4):745-52.

120.Prasad G,Wang H, Agrawal S, Zhang R. Antisense oligonucleotides targeted to MDM2 oncogene as a novel approach to the treatment of glioblastoma multiforme.Anticancer Res. 2002 Apr;22:107-16.

121.Wang H,Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Anti-tumor efficacy of a novel antisense anti-mdm2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.Mol Med.2002 Apr;8(4):185-99.

122.Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.Clin Cancer Res.2001 Nov;7(11):3613-24.

123.Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics.Curr Cancer Drug Targets.2001 Nov;1(3):177-96.

124.Zhang R,Wang H. MDM2 Oncogene as a novel target for human cancer therapy.Curr Pharm Des.2000 Mar;6(4):393-416.

125.Zhang R,Wang H. Antisense oligonucleotides as anticancer therapeutics.Recent Research Development in Cancer, 2000;2:61-76.

126.Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W, Agrawal S, Zhang R. MDM2 oncogene as a target for cancer therapy: An antisense approach.Int J Oncol.1999;15(4):653-60.

127.Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIa subunit of protein kinase A after oral administration.Proc Natl Acad Sci USA.1999;96(24):13989-94.